2SARS-CoV-2 Testing Strategies for Outbreak Mitigation

3in Vaccinated Populations

1

11

4Chirag K. Kumar¹, Ruchita Balasubramanian², Stefano Ongarello³, Sergio Carmona^{3, 4}, and 5Ramanan Laxminarayan^{1, 2, *}

- 6¹ Princeton University, Princeton NJ, USA
- 7² Center for Disease Dynamics, Economics & Policy, New Delhi, India
- 8³ Foundation for Innovative New Diagnostics, Geneva, Switzerland
- 9⁴ University of Witwatersrand, Johannesburg, South Africa
- 10* Corresponding author: ramanan@cddep.org

12Abstract

- Although COVID-19 vaccines are globally available, waning immunity and emerging 14vaccine-evasive variants of concern have hindered the international response as COVID-19 cases 15continue to rise. Mitigating COVID-19 requires testing to identify and isolate infectious 16individuals. We developed a stochastic compartmentalized model to simulate SARS-CoV-2 17spread in the United States and India using Reverse Transcriptase Polymerase Chain Reaction 18(RT-PCR) assays, rapid antigen tests, and vaccinations. We detail the optimal testing frequency 19and coverage in the US and India to mitigate an emerging outbreak even in a vaccinated 20population: overall, maximizing frequency is more important, but high coverage remains 21necessary when there is sustained transmission. We show that a resource-limited vaccination 22strategy still requires high-frequency testing and is 16.50% more effective in India than the 23United States. Tailoring testing strategies to transmission settings can help effectively reduce 24cases more than if a uniform approach is employed without regard to differences in location.
- 25 **Key Words and Phrases:** COVID-19, SARS-CoV-2, individual-based modeling, agent-26based modeling, vaccines, LMICs.

1. INTRODUCTION

- 28 Since the emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in 29Wuhan, China in late 2019, the coronavirus disease (COVID-19) pandemic has resulted in more 30than 280 million reported cases and 5.4 million reported deaths worldwide as of January 1, 312022¹. Despite efforts to curb the spread of SARS-CoV-2 through restrictions on travel², 32business openings³, and personal measures⁴—including mask wearing and social distancing— 33cases have continued to rise in many countries⁵. Although vaccines against COVID-19 are 34available, the emergence of variants of concern⁶ that are only partially neutralized by existing 35antibodies or prior vaccination and are more contagious along with waning immunity has 36resulted in widespread COVID-19 outbreaks even in highly vaccinated populations⁹. Likewise. 37many populations, particularly in low- and middle-income countries, still lack widespread access 38to vaccines and continue to experience significant excess mortality¹⁰. All these factors must be 39simultaneously considered when developing mitigation strategies for emerging outbreaks. 40Consequently, it appears likely that SARS-CoV-2 will continue to pose a threat to public health 41 for many years even if vaccines are distributed widely because of the rapid evolution of variants 42of concern. Thus, testing and containment will continue to be critical to COVID-19 response and 43mitigation.
- Because of the high transmission rate of SARS-CoV-2 and prevalence of asymptomatic

 45carriers¹¹, accurate, efficient, and pervasive testing methods are needed to track and contain

 46disease spread. Currently, two main diagnostic methods are widely used¹². *Reverse Transcriptase*47*Polymerase Chain Reaction* (RT-PCR), which is considered to be the gold standard, detects the

 48presence of viral RNA in respiratory samples¹³. Although highly sensitive, test results typically

 49require two to three days¹⁴, during which an infected individual may continue transmitting the

50virus. *Later flow rapid antigen tests* can be read in less than an hour¹⁵, and an individual who 51tests positive can immediately self-isolate. However, rapid antigen tests require a higher viral 52load for positive detection, must be tailored to the antigens on a specific variant, and may not 53return a positive result for infectious individuals past the early stages of their infection¹⁶.

- Testing is only effective when individuals who test positive are quarantined, so they will not 55continue to transmit the disease further; essentially, testing and subsequent quarantining 56minimizes the effective duration during which an individual may spread the disease. However, 57testing usually only occurs in a reactionary fashion: for instance, an individual exhibits symptom 58that may be attributed to COVID-19 and the individual is tested, an individual comes in close 59contact with an infected person, or an individual seeks to travel and must show proof of a 60negative test. This type of testing is not optimized towards minimizing cases but rather just 61identifies current cases. Comparatively, proactive testing where testing is required within a 62community–such as with a college campus, business, or factory–is far more likely to be effective 63as it is more likely to capture asymptomatic spreaders.
- Although both RT-PCR and antigen tests could play a role in COVID-19 containment, there 65is lack of clarity on the optimal coverage and frequency with which these tests should be used, 66and how they may be combined to greatest effect. Moreover, while COVID-19 has affected 67populations around the world regardless of socioeconomic status¹⁷, there are significant 68differences in transmission intensity by setting¹⁸. Tailored testing strategies that are specific to 69the local transmission context may be superior to applying a one-size-fits all method for all 70populations. Guidance on testing strategies may differ by transmission setting (i.e., in high-71income countries, such as the United States, versus low- and middle-income countries, such as 72India) as not only do transmission dynamics differ¹⁸ but low- and middle-income countries

73(LMICs) now have the majority of confirmed COVID-19 cases¹ along with more barriers to 74adequate health care¹⁹. Significant effort has been directed at containment strategies across high 75income countries in Europe and North America^{20–24}, but these findings cannot be generalized to 76all countries worldwide²⁵ because of differences in transmission intensity. Moreover, for 77COVID-19 to become globally endemic, it must be controlled in all countries, so determining 78setting-specific mitigation strategies and characterizing how vaccines and testing may be used in 79tandem is critical to international public health efforts to move towards the post-pandemic phase. 80 Here, we used a stochastic, compartmentalized, agent-based model (ABM) to simulate 81COVID-19 transmission dynamics in the United States and India under different proactive 82testing scenarios and vaccination potentials. We evaluated various strategies for COVID-19 83control in both countries to identify their efficacy and costs and determine how testing 84recommendations may differ by transmission setting for mitigating an outbreak even in highly-85vaccinated populations. Our simulation results can be directly applied to community settings, 86such as office buildings, factories, or campuses, that are trying to reopen safely and with minimal 87disease spread.

88 2. RESULTS

Before evaluating the effect of our testing scenarios, we ran our model without any 90mitigation (Fig. S1; Table S1) to validate our ability to recreate observed COVID-19 91characteristics. The model-estimated case-fatality ratio (CFR) for the United States is 2.66% 92[95% percentile credible interval from 200 independent realizations of the ABM 2.17–3.12%], 93and the actual CFR at time of writing is 3.05% ²⁶; likewise, the model-estimated CFR for India is 941.85% [1.47–2.25%] and the actual CFR based on available data is 2.11% ¹⁸. Since our model

95recreated the expected dynamics, we could justify the use of this model to identify the efficacy 96and trade-offs of testing strategies and vaccinations in both settings.

97Proactive Testing to Mitigate an Emerging Outbreak

The B.1.1.529 SARS-CoV-2 variant (designated "Omicron" by the World Health 99Organization) has shown almost complete evasion to existing vaccines or immunity from prior 100infection. Based on Omicron's observed infectivity even in highly vaccinated populations, we 101modeled the impact of RT-PCR or antigen testing on a representative population in the US (Fig. 1021) or India (Fig. 2) by proactively testing at various frequencies (quantified as days between 103tests) and coverages (quantified as the fraction of people surveilled each time testing is done). 104While the cost of the surveillance depended only on the rate of testing (i.e., average number of 105tests administered per day), the risk of infection depended on the frequency, coverage, type of 106test used, and transmission setting, with each test and setting placing different importance on 107frequency and coverage (Fig. S3).

Overall, for the same coverage and frequency of testing, using RT-PCR assays resulted in 10912.65% [7.01% – 18.30%] more cases than antigen tests in the US and 9.30% [4.75% – 13.85%] 110more cases in India (Figs. 1-2), likely because RT-PCR tests require a two-to-three-day 111turnaround time during which infected individuals may continue transmitting (Fig. S2). Rapid 112antigen tests are also up to 20 times cheaper, allowing for further screening than RT-PCR assays 113with the same financial budget (Fig. 2). Ultimately, when used frequently and widely, antigen 114tests were notably better than RT-PCR assays (Fig. S3, S4, S5). Nevertheless, at low coverage 115and frequency, neither test was effective at mitigation.

Explanatory regression models that predicted the percent infected for each setting from 117 frequency, coverage, and test used (R^2 of all models >90%; Table S2) indicated that use of

118antigen tests versus RT-PCR tests resulted in 3.12% [95% confidence interval on the regression 119coefficients 1.73–4.51] fewer cases in the United States and 1.99% [95% CI 1.02–2.97] fewer 120cases in India. Independent of test, maximizing frequency had a larger effect on mitigating cases 121than maximizing coverage, with a 3.71-fold [2.99–4.43] greater effect in the United States and a 1225.01-fold [4.15–5.87] greater effect in India. In other words, given resource constraints, the 123frequency of testing (i.e., the inverse of the number of days between subsequent test 124administrations) should be 3.71 and 5.01 times greater than the coverage (i.e., the number of 125testing administrations required to surveil the whole population) in the United States and India, 126respectively. Though frequency dominates overall, the importance of coverage differed by test. 127When RT-PCR tests were used rather than antigen tests, maximizing coverage has a 14.24% 128[10.71–17.76] greater effect on reducing cumulative infections in the United States and a 6.84% 129[4.89-8.79] greater effect in India. Nevertheless, use of antigen tests was more effective than use 130of RT-PCR tests, especially when used frequently.

While we observe the same general trends in both settings, frequency is more important in 132India than in the United States: Figs. 1 and 2 show a strong gradient of increasing cases as testing 133frequency is decreased, most noticeably for antigen testing and especially for India. However, we 134observe that at low coverage, the effect of frequency is much less in India. High-frequency, low-135coverage testing can still be useful in the United States, but we did not observe the same pattern 136in India, where coverage must be relatively high for effective mitigation. Although increasing 137coverage when it was low had little benefit, increasing coverage from half of the population 138surveilled to the whole population surveilled had a larger effect in India. Ultimately, though 139frequency may still have dominated overall, increasing coverage was also critical in certain 140testing scenarios in India. Additionally, we conducted sensitivity analyses by running canonical

141strategies with R_{eff} from 2.5 (used in all main figures and analyses; Fig. S6, Fig. S7) and 142decreasing R_{eff} to R_{eff} = 2 (Fig. S8) and 1.5 (Fig. S9). Our main findings and trends still held 143across all values of R_{eff} , though there are fewer cases with a lower R_{eff} .

144*Utilizing Combinations of Tests and Vaccines*

- Emerging variants of concern are not only vaccine-evasive but often more transmissive. To 146identify and isolate transmissive individuals as quickly as possible, we propose a mixed strategy 147that utilizes the complementary nature of antigen tests and RT-PCR assays (i.e., antigen tests 148excel when used frequently whereas RT-PCR assays are more effective when used widely). All 149individuals were tested weekly using antigen tests and all negative results were followed up 150immediately by an RT-PCR assay (Fig. 3). Since RT-PCR assays have higher sensitivity, their 151use as a follow-up should allow for the detection of individuals with a viral load too low to be 152detected by an antigen test. Nevertheless, this was resource intensive: it potentially required 153more than just one test per individual.
- Such a mixed strategy was effective in both settings—resulting in minimal hospitalizations 155 and deaths—but more effective in reducing cases India than in the United States. Compared with 156 weekly antigen testing (Fig. S7), this approach did not significantly reduce cases in the United 157 States ($\lambda = 2.25$, p = 0.13) or India ($\lambda = 1.00$, p = 0.32). Nevertheless, this strategy resulted in 158 reaching 1% incidence 7.0 [0.0–14.0] ($\lambda = 9.25$, p < 0.005) days earlier in the United States and 1597.0 [–7.0–7.0] days earlier ($\lambda = 5.81$, p = 0.016) in India. In practice, effective mitigation of 160 SARS-CoV-2 or conferring immunity through vaccination or booster shots can allow testing to 161 slow down and be less extensive, decreasing the required cost of testing. However, testing should 162 only stop after SARS-CoV-2 infections have dropped below a level where they are no longer 163 able to trigger widespread transmission or enough individuals are vaccinated (such external

164factors are not considered in our simulations as they are highly variable and differ between 165transmission setting). Nevertheless, we show that effective surveillance is critical especially in 166the early stages of transmission to mitigate disease burden from contagious variants of concern. 167 Likewise, the rapid emergence of variants of concern has placed an emphasis on widespread 168vaccination campaigns and now even booster shots for some populations. Nevertheless, key 169 questions remain about optimal testing strategies and epidemic trajectories for populations as 170vaccines are administered or additional immunity is conferred through booster shots. Thus, we 171determined how proactive testing and simple vaccination strategies can be used together to 172promote SARS-CoV-2 reaching the endemic phase. Disease surveillance, continued testing, and 173 vigilance remain critical even as more individuals become vaccinated. Note that while there are 174studies detailing optimal vaccine allocation strategies²⁷, our goal is not optimize the distribution 175 of vaccines but rather determine the impact of vaccines in a resource-limited distribution scheme 176and how vaccines must be coupled with testing to mitigate disease spread. We couple daily 177 vaccinations with antigen testing 100% of the population weekly and antigen testing 33.3% of 178the population weekly (i.e., see Fig. S7 for these scenarios but without vaccines) in both settings. 179 Overall, vaccines are mostly effective in reducing COVID-19 cases at both coverages and 180in both transmission settings. First, compared to there being no vaccinations or immunity, 20% 181 vaccines coupled with weekly antigen testing 100% of the population resulted in 15.12% [6.39 – 18225.50] ($\lambda = 396.01$, $p < 10^{-6}$) fewer cases in India than without vaccines. However, surprisingly, 183the limited distributions of vaccines only reduced cases marginally in the US compared to 184weekly antigen testing alone ($\lambda = 1.69$, p = 0.19). Secondly, we observe that the increasing 185number of vaccinations resulted in a mitigated disease course; concretely, we observed that

186vaccines coupled with weekly antigen testing 100% of the population resulted in infections

187below 0.5% incidence 7.0 [0 - 15.0] ($\lambda = 45.00$, $p < 10^{-6}$) days faster in the US and 70.0 [34.83 – 188126.0] ($\lambda = 372.49$, $p < 10^{-6}$) days faster in India than the same testing strategy but with no 189vaccines. However, widespread testing is still critical, especially in early phases of vaccine 190distribution where we note many antigen-positive SARS-CoV-2 cases being captured. We also 191found marked differences between testing 100% of population weekly or 33.3% of the 192population weekly: specifically, testing 100% of the population weekly resulted in 30.83% 193[20.41 – 33.10] ($\lambda = 342.25$, $p < 10^{-6}$) fewer cases in the US and 12.99% [7.65 –18.58] ($\lambda = 194396.01$, $p < 10^{-6}$) fewer cases in India than testing 33.3% of the population weekly, suggesting 195high frequency testing remains critical even with vaccines.

Nevertheless, while vaccines are effective in both transmission settings, there are key 197differences in the corresponding disease courses and number of infections by transmission 198setting. In particular, as discussed above, cases peak earlier in the US than in India, and as a 199result of distributing vaccines while there is still transmission in India, there were 16.50% [3.83 – 20033.17] ($\lambda = 396.01$, $p < 10^{-6}$) fewer cases in India than the US for antigen testing 100% of the 201population weekly. Furthermore, we also noted that using vaccines reduced the cost of testing 202because vaccinated individuals are not tested. Ultimately, the use of vaccines is effective in 203minimizing cases when coupled with testing and can be a tailored strategy to mitigate ongoing 204outbreaks.

205 **4. DISCUSSION**

206Maximizing the Effectiveness of Testing Strategies

Our results provide insight into constructing testing strategies with maximum effectiveness.

208First, antigen tests are more effective than RT-PCR tests across both transmission settings

209because they enable faster action to reduce transmission; our results agree with real-world 210evidence that antigen tests have been used successfully in nation-wide testing campaigns^{28,29}. We 211observe that RT-PCR assays are more comparable to antigen tests as their turnaround time is 212decreased³⁰ (Fig. S2). Nevertheless, the increased mitigation of antigen tests compared with RT-213PCR assays with standard turnaround times is most pronounced when 100% of the population is 214tested weekly. Since antigen tests have a quicker turnaround time, infected individuals are more 215likely to self-isolate faster. Our simulations show that use of antigen tests results in a lower peak 216of daily cases compared with RT-PCR assays. Because disease spread is greatest in the early 217stages, when most of the population is still susceptible, early isolation of infected individuals is 218critical to mitigating disease spread³¹, especially critical when considering highly contagious and 219vaccine-evasive variants of concern. Additionally, SARS-CoV-2 transmission to secondary 220individuals is significant even immediately after initial infection³² (Fig. S9), further underscoring 221the need for isolating infectious individuals quickly.

We show that that high-frequency testing must be prioritized when fighting an emerging 223outbreak driven by a contagious variant of concern, though the relative importance of frequency 224versus coverage differs by setting and the type of test used. Maximizing frequency has the 225greatest importance for antigen testing. This is likely driven by its lower sensitivity but quicker 226turnaround: since antigen tests are unable to detect infected individuals with low viral loads, they 227must be used frequently to identify when individuals become infectious past detectable levels 228and force them to isolation. On the other hand, RT-PCR assays can still be effective when used 229widely because they can identify infectious individuals with low viral loads. Moreover, frequent 230use of antigen tests is not substantially better than even more extensive disease mitigation

231strategies, such as coupling antigen and RT-PCR tests, and is still effective in scenarios where 232there may even be unmitigated disease spreaders.

Although we observe mostly similar trends in mitigation strategies between the two

233Comparison of Testing Effectiveness between the United States and India

234

235countries, some differences are important for tailoring mitigation solutions. First, while both 236transmission settings have the same R_{eff} and are parametrized with the same incubation period 237 and transmission distribution, the disease trajectory is markedly different. Overall, transmission 238is shorter, reaches a higher peak in percentage infected, peaks earlier, and the credible intervals 239are substantially larger in the United States than India—all of which can be explained by the 240contact matrices and the inherent variability in contact patterns¹⁸; moreover, our findings 241generally agree with real world analyses of SARS-CoV-2 spread in the US^{33,34}. Notably, the 242 large credible intervals in the United States are likely driven by the high variability in the 243 distribution of infected secondary contacts³⁵. Moreover, these differences affect mitigation 244effectiveness. We note that sustained transmission in India, which our simulation predicts, is 245similar to what is actually occurring in India and contributing to observed resurgences of cases³⁶. 246 While our simulations overall indicate that high-frequency testing must be an urgent 247priority, we also find that the importance of frequency and coverage differs by transmission 248setting. Whereas increasing frequency is overall more important in India, increasing coverage 249beyond half of the population surveilled at each testing occurrence is critical for markedly 250improved mitigation and for the benefits of frequency to be most noticeable. Notably, at lower 251coverages, increasing frequency is more beneficial than increasing coverage. Consequently, we 252suggest that with limited resources, frequency should be prioritized unless coverage can be 253increased beyond half of the population surveilled; likewise, at those high coverages, the

254importance of frequency is most evident. Ultimately, the need for widespread and frequent 255antigen testing is urgent in both countries, but the trade-off between frequency and coverage 256should be tailored to community needs.

257 Moreover, we find antigen testing is not only more effective but also substantially cheaper 258than use of RT-PCR assays. Our simulations show that given a constant budget constraint, 259antigen testing can be done more frequently or at wider coverage and result in fewer cases than 260use of RT-PCR assays. Nevertheless, we also observe that the same testing scenario may have 261different costs in the United States versus India. In our simulation, we assume that all individuals 262who have not been infected must be tested. Since in the United States the peak in cases occurs 263earlier, more individuals are infected in the early stages and thus a typical individual is removed 264from the testing pool faster than in India. Although the cost of testing thus should be lower in the 265United States and we do observe this in many of our simulations, in certain scenarios (e.g., where 266antigen tests are used at high frequency and coverage; Fig. 2), the cost is less in India because the 267testing strategy is less effective. Since in India more individuals are infected and do not need to 268be tested, the cost of the strategy falls. However, given the differential nature of disease spread, 269testing frequency and coverage can change as the epidemic progresses, which may also change 270the cost (not considered in our simulations). Finally, we do not consider the cost of hospital beds 271or self-isolation, which likely differ heavily between settings. Additionally, our analysis does not 272explicitly consider contact tracing or self-isolation of individuals who experience symptoms, so 273 our results more directly indicate the impact of proactive testing and immediate quarantining. 274 Finally, we show that vaccines and testing can be combined to create mitigation strategies 275that mitigate the duration of sustained transmission and can usher in an endemic phase earlier. 276Even a resource-limited vaccine allocation strategy of simply distributing vaccines randomly to

277susceptible individuals in addition to testing some of the population weekly is effective in 278minimizing cases and ending sustained transmission earlier in both transmission settings (Fig. 4). 279However, we show that vaccinations have different impacts in each transmission setting. In 280particular, the vaccination strategy utilized is more effective in reducing cases in India than the 281US. This is likely due to the sustained nature of SARS-CoV-2 transmission observed naturally in 282India (Fig. S1); consequently, the impact of continued vaccinations is greater in India as 283supposed to the US where infections peak much earlier. Thus, our findings show that vaccines 284are critical to minimizing the chance of future waves of COVID-19 cases especially as much of 285the world's population still remains susceptible to SARS-CoV-2. Nevertheless, we note that 286widespread testing is still critical, especially in the early phases of vaccine distribution when 287vaccines are limited. Moreover, testing will likely continue to be critical as further variants of 288concern that may be vaccine-resilient or even vaccine-resistant continue to emerge and must be 289monitored to ensure that resurgences of SARS-CoV-2 infections do not occur³⁷.

Generally, the most effective of the testing strategies discussed in this paper are frequently 291not the most expensive but rather those that are most closely tailored to the dynamics of the 292setting. Therefore, identifying transmission dynamics across a wide range of settings and 293applying specialized testing scenarios to specific environments are critical to effective 294mitigation. Our study suggests that contact matrices specific to the setting must be used as 295opposed to generic contact matrices³⁸ commonly used in modeling studies. Our simulation shows 296that social mixing patterns affect the efficacy of mitigation strategies. However, we acknowledge 297that in developing tailored scenarios, considering social factors is also crucial, since health 298behaviors have been shown to be related to social clustering^{39–41}. Nevertheless, we believe the

299trade-offs presented in this paper present a useful set of heuristics that can inform testing 300strategies and health policy across a wide range of settings.

301 **5. METHODS**

Accurately simulating SARS-CoV-2 dynamics requires two types of data: details of disease 303outcomes (i.e., data regarding COVID-19's effects in humans), and attributes of virus spread 304(i.e., properties of SARS-CoV-2 transmission). Details of disease outcomes include such effects 305as whether an infection will result in hospitalization. Attributes of virus spread refer to the 306disease's epidemiology, such as the Reff and viral shedding by day. We gathered both kinds of 307data through freely and publicly available sources for both transmission settings.

308COVID-19 Characteristics

We obtained data on COVID-19 cases and death counts from the beginning of data 310acquisition in the United States and India: US data were obtained from the National Center for 311Health Statistics (of the US Centers for Disease Control and Prevention, CDC)²⁶, and data from 312India were obtained from previous studies^{18,42}. We assign each individual an age, gender, and 313comorbidity based on census data and comorbidity prevalence⁴³. We used these data to estimate 314COVID-19 probability of death given age, gender, and comorbidities. Additionally, the CDC 315keeps data on the probability of hospitalization and summary statistics (i.e., the 25th, 50th, and 31675th percentile) for time spent in the hospital due to severe COVID-19 infection⁴⁴. Although 317having the distribution of hospital stay duration would be ideal, based on empirical evidence that 318such data follow a negative binomial distribution⁴⁵, we construct negative binomial distributions 319with the same summary statistics to generate an estimated probability for various lengths of 320hospital stays. We had different hospitalization rates in the United States and India, but we

321assume that the pattern of hospital stay length is maintained between the two countries, since 322there is a shortage of data on COVID-19 hospitalizations in India. Ultimately, drawing from 323empirical evidence of COVID-19 effects, we project the expected outcome of individuals' 324infection given their age, gender, and comorbidities, including whether they are hospitalized, 325time spent in hospital, and whether they die.

326SARS-CoV-2 Tests

We considered two types of tests in our simulations: RT-PCR assays and antigen tests. The 328sensitivity and specificity as a function of viral load of each test are given in Table S3. From 329current data, we used a turnaround time of three days for RT-PCR assays¹⁴. We assumed antigen 330test results come back quickly enough that an infectious individual will not further spread the 331virus while waiting for results. Finally, drawing from current estimates of costs for these tests, 332we assumed a cost of each test (Table S3), but note that costs may change dramatically based on 333setting and health insurance coverage. All individuals who do not yet have a documented 334infection are tested. Likewise, based on current evidence, fully vaccinated individuals (i.e., either 335those with a two-dose regiment of an mRNA vaccine or a single dose of another WHO approved 336vaccine) experience a decreased probability of transmitting the disease, and further booster shots 337increase the chance that a vaccinated but infected individual will not transmit to their contacts.

338SARS-CoV-2 Epidemiology

Although the above data determine the effects of COVID-19 for an individual, they do not 340detail how SARS-CoV-2 spreads in a population. Thus, to simulate SARS-CoV-2 transmission, 341we gathered data on the incubation period⁴⁶, transmission probability since infection³², and 342inferred viral load after symptoms⁴⁷. Together, these variables detailed the necessary information 343for SARS-CoV-2 transmission from an infected individual to secondary contacts by day and

344whether the individual will be flagged as infectious by a test. Despite extensive data along with 345quantifiable uncertainty for the incubation period, transmission probability since infection, and 346viral load after symptom onset of SARS-CoV-2 (see Table S3 for the parameters used in our 347analysis), quantifying viral load prior to symptom onset is more difficult and there is sometimes 348contradictory evidence on the peak viral load^{48,49}. Thus, we drew from previous viral kinetics 349models to infer the viral load prior to symptom onset; note that our results are likely robust to 350changes in viral load distribution as there is variability in our estimated viral loads by individual 351(Fig. S9). Specifically, we say that viral load peaks anywhere from day 0 to day 4 after symptom 352onset⁵⁰; the peak is anywhere from 5 to 11 log10 virions per mL⁴⁷, that log10 viral load increases 353linearly from negative infinity on the day of infection to the aforementioned peak, and that log10 354viral load decays from peak to the end of the individual's infection linearly with a slope drawn 355from meta-analyses⁴⁷. See Fig. S9 for our inferred viral load distributions.

Additionally, we gathered data on contact matrices and the distribution for the number of 357secondary cases arising from an infected individual for each transmission setting^{18,51}. These 358variables were used for determining how many infections may arise from a single infected 359individual and the likely age of the consequently infected individuals. Table S3 shows a 360complete list of parameters compiled to simulate SARS-CoV-2 transmission in our model. From 361these parameters, we simulated realistic disease spread in a population across settings.

362Model Description

We developed a stochastic, compartmentalized, empirically driven agent-based model 364(ABM) to project COVID-19 cases, hospitalizations, and deaths given a variety of testing 365strategies. We adopted the following structure in our model: individuals in the population start as 366"susceptible" or "recovered" if they have previously been infected before entry into our

367simulation. Susceptible individuals can become "infected and not expressing symptoms" after a 368positive transmission event with another infected individual. Individuals can either stay as 369"infected and not expressing symptoms" (i.e., "asymptomatic") for the duration of their infection 370or move to "infected and expressing symptoms". Infected and symptomatic individuals may 371either recover or become hospitalized. Finally, hospitalized individuals may either recover or die 372(see Table S3 for the probability and duration of each event). Throughout each phase, the 373 individual's probability of transmitting the virus changes (peaking near symptom onset), as does 374the viral load (peaking shortly after symptom onset). We inferred the viral load before symptom 375onset based on previous studies³⁰ and drew the viral load after symptom onset from meta-376analyses⁴⁷. Nevertheless, not all individuals will transmit the virus: in accordance with 377"superspreading"⁵², we drew the number of positive contacts for infected individuals from a 378negative binomial distribution, and whom they are likely to infect, from contact matrices. 379Individuals interacted homogeneously with each other in Brownian fashion in an open space 380with dimensions tuned to ensure the R_{eff} is 2.5 without any mitigation. ABMs present two 381benefits over traditional deterministic compartmentalized models: (i) implementing individual 382specificity is easier, and (ii) they are inherently stochastic and thus can provide credible ranges of 383the epidemic trajectory given initial conditions. Each model was run in the following way: there 384are 5,000 individuals with age and genders drawn from US and Indian census data, and 385comorbidities drawn from recorded prevalences given age and gender in 2017. Note that these 386parameters can be easily changed so that policymakers can determine which mitigation and 387testing strategies are most effective for specific communities. We ran each model for 200 days 388(until a steady state is reached), 200 times (i.e., independent replications), and present the 50th, 3892.5th, 25th, 75th, and 97.5th percentiles (i.e., the "credible intervals") as summary statistics in

390figures; when reporting values in the main text, we simply provide the 50th percentile and the 3912.5th and 97.5th percentiles as the credible interval. We use standard methods of propagating 392uncertainty in variables to ensure meaningful credible intervals⁵³. Unless otherwise mentioned, 393to test for statistically significant difference in medians between two distributions, we use a two-394sided paired Mood's Median test⁵⁴. The model was developed in Python⁵⁵ using the Mesa 395package under the Apache2 license⁵⁶. All subsequent analyses were done in Python.

397**REFERENCES**

- 3981. Dong, E., Du, H. & Gardner, L. An interactive web-based dashboard to track COVID-19 in
- 399 real time. *Lancet Infect. Dis.* **20**, 533–534 (2020).
- 4002. Wells, C. R. et al. Impact of international travel and border control measures on the global
- spread of the novel 2019 coronavirus outbreak. *Proc. Natl. Acad. Sci.* **117**, 7504–7509
- 402 (2020).
- 4033. Brauner, J. M. et al. Inferring the effectiveness of government interventions against COVID-
- 404 19. Science (2020).
- 4054. Chernozhukov, V., Kasahara, H. & Schrimpf, P. Causal impact of masks, policies, behavior
- 406 on early Covid-19 pandemic in the US. *J. Econom.* **220**, 23–62 (2020).
- 4075. Chookajorn, T., Kochakarn, T., Wilasang, C., Kotanan, N. & Modchang, C. Southeast Asia
- 408 is an emerging hotspot for COVID-19. *Nat. Med.* **27**, 1495–1496 (2021).
- 4096. Walensky, R. P., Walke, H. T. & Fauci, A. S. SARS-CoV-2 variants of concern in the United
- 410 States—Challenges and opportunities. *Jama* **325**, 1037–1038 (2021).
- 4117. Cele, S. et al. SARS-CoV-2 Omicron has extensive but incomplete escape of Pfizer
- 412 BNT162b2 elicited neutralization and requires ACE2 for infection. *MedRxiv* (2021).
- 4138. Goldberg, Y. et al. Waning immunity after the BNT162b2 vaccine in Israel. N. Engl. J. Med.
- 414 **385**, e85 (2021).
- 4159. Brown, C. M. et al. Outbreak of SARS-CoV-2 infections, including COVID-19 vaccine
- breakthrough infections, associated with large public gatherings—Barnstable County,
- 417 Massachusetts, July 2021. *Morb. Mortal. Wkly. Rep.* **70**, 1059 (2021).
- 41810. Lewnard, J. A. et al. All-cause mortality during the COVID-19 pandemic in Chennai, India:
- an observational study. *Lancet Infect. Dis.* (2021).

- 42011. Lee, E. C., Wada, N. I., Grabowski, M. K., Gurley, E. S. & Lessler, J. The engines of SARS-
- 421 CoV-2 spread. *Science* **370**, 406 (2020).
- 42212. Smithgall, M. C., Dowlatshahi, M., Spitalnik, S. L., Hod, E. A. & Rai, A. J. Types of Assays
- 423 for SARS-CoV-2 Testing: A Review. *Lab. Med.* **51**, e59–e65 (2020).
- 42413. Williams, E., Bond, K., Zhang, B., Putland, M. & Williamson, D. A. Saliva as a non-
- invasive specimen for detection of SARS-CoV-2. *J. Clin. Microbiol.* (2020).
- 42614. Quest Diagnostics. Quest Diagnostics Media Statement about COVID-19 Testing. (2020).
- 42715. Zhen, W., Smith, E., Manji, R., Schron, D. & Berry, G. J. Clinical evaluation of three
- sample-to-answer platforms for detection of SARS-CoV-2. *J. Clin. Microbiol.* **58**, (2020).
- 42916. Hirotsu, Y. et al. Comparison of automated SARS-CoV-2 antigen test for COVID-19
- infection with quantitative RT-PCR using 313 nasopharyngeal swabs, including from seven
- 431 serially followed patients. *Int. J. Infect. Dis.* **99**, 397–402 (2020).
- 43217. Chowdhury, R. et al. Dynamic interventions to control COVID-19 pandemic: a multivariate
- prediction modelling study comparing 16 worldwide countries. Eur. J. Epidemiol. 35, 389–
- 434 399 (2020).
- 43518. Laxminarayan, R. et al. Epidemiology and transmission dynamics of COVID-19 in two
- 436 Indian states. *Science* **370**, 691–697 (2020).
- 43719. Peters, D. H. et al. Poverty and access to health care in developing countries. Ann. N. Y.
- 438 *Acad. Sci.* **1136**, 161–171 (2008).
- 43920. Asgary, A., Cojocaru, M. G., Najafabadi, M. M. & Wu, J. Simulating preventative testing of
- 440 SARS-CoV-2 in schools: policy implications. *BMC Public Health* **21**, 1–18 (2021).
- 44121. Wilder, B. et al. Modeling between-population variation in COVID-19 dynamics in Hubei,
- 442 Lombardy, and New York City. *Proc. Natl. Acad. Sci.* **117**, 25904–25910 (2020).

- 44322. Hoertel, N. et al. A stochastic agent-based model of the SARS-CoV-2 epidemic in France.
- 444 *Nat. Med.* **26**, 1417–1421 (2020).
- 44523. Moghadas, S. M. et al. Projecting hospital utilization during the COVID-19 outbreaks in the
- 446 United States. *Proc. Natl. Acad. Sci.* **117**, 9122–9126 (2020).
- 44724. Kucharski, A. J. et al. Effectiveness of isolation, testing, contact tracing, and physical
- distancing on reducing transmission of SARS-CoV-2 in different settings: a mathematical
- 449 modelling study. *Lancet Infect. Dis.* **20**, 1151–1160 (2020).
- 45025. Walker, P. G. et al. The impact of COVID-19 and strategies for mitigation and suppression
- in low-and middle-income countries. *Science* **369**, 413–422 (2020).
- 45226. CDC. COVID-19 Cases, Deaths, and Trends in the US | CDC COVID Data Tracker. Centers
- 453 for Disease Control and Prevention https://covid.cdc.gov/covid-data-tracker (2020).
- 45427. Bubar, K. M. et al. Model-informed COVID-19 vaccine prioritization strategies by age and
- 455 serostatus. Science (2021).
- 45628. Pavelka, M. et al. The impact of population-wide rapid antigen testing on SARS-CoV-2
- 457 prevalence in Slovakia. *Science* **372**, 635–641 (2021).
- 45829. Boum, Y. et al. Performance and operational feasibility of antigen and antibody rapid
- diagnostic tests for COVID-19 in symptomatic and asymptomatic patients in Cameroon: a
- 460 clinical, prospective, diagnostic accuracy study. *Lancet Infect. Dis.* (2021).
- 46130. Larremore, D. B. et al. Test sensitivity is secondary to frequency and turnaround time for
- 462 COVID-19 screening. *Sci. Adv.* eabd5393 (2020).
- 46331. Worobey, M. et al. The emergence of SARS-CoV-2 in Europe and North America. Science
- 464 **370**, 564–570 (2020).

- 46532. He, X. et al. Temporal dynamics in viral shedding and transmissibility of COVID-19. Nat.
- 466 *Med.* **26**, 672–675 (2020).
- 46733. Monod, M. et al. Age groups that sustain resurging COVID-19 epidemics in the United
- 468 States. *Science* **371**, (2021).
- 46934. Pei, S., Kandula, S. & Shaman, J. Differential effects of intervention timing on COVID-19
- 470 spread in the United States. *Sci. Adv.* **6**, eabd6370 (2020).
- 47135. Endo, A., Abbott, S., Kucharski, A. J. & Funk, S. Estimating the overdispersion in COVID-
- 472 19 transmission using outbreak sizes outside China. Wellcome Open Res. 5, 67 (2020).
- 47336. Thiagarajan, K. Why is India having a covid-19 surge? (2021).
- 47437. Walensky, R. P., Walke, H. T. & Fauci, A. S. SARS-CoV-2 variants of concern in the United
- 475 States—Challenges and opportunities. *JAMA* **325**, 1037–1038 (2021).
- 47638. Mossong, J. et al. Social contacts and mixing patterns relevant to the spread of infectious
- 477 diseases. *PLoS Med* **5**, e74 (2008).
- 47839. Verelst, F., Willem, L. & Beutels, P. Behavioural change models for infectious disease
- 479 transmission: a systematic review (2010–2015). J. R. Soc. Interface 13, 20160820 (2016).
- 48040. Reid, A. E., Cialdini, R. B. & Aiken, L. S. Social norms and health behavior. in *Handbook of*
- behavioral medicine 263–274 (Springer, 2010).
- 48241. Christakis, N. A. & Fowler, J. H. The spread of obesity in a large social network over 32
- 483 years. N. Engl. J. Med. **357**, 370–379 (2007).
- 48442. Barman, M. P., Rahman, T., Bora, K. & Borgohain, C. COVID-19 pandemic and its
- recovery time of patients in India: A pilot study. *Diabetes Metab. Syndr. Clin. Res. Rev.* 14,
- 486 1205–1211 (2020).

- 48743. James, S. L. et al. Global, regional, and national incidence, prevalence, and years lived with
- disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a
- 489 systematic analysis for the Global Burden of Disease Study 2017. The Lancet 392, 1789–
- 490 1858 (2018).
- 49144. CDC. Healthcare Workers. Centers for Disease Control and Prevention
- 492 https://www.cdc.gov/coronavirus/2019-ncov/hcp/planning-scenarios.html (2020).
- 49345. Carter, E. M. & Potts, H. W. Predicting length of stay from an electronic patient record
- 494 system: a primary total knee replacement example. *BMC Med. Inform. Decis. Mak.* **14**, 26
- 495 (2014).
- 49646. McAloon, C. et al. Incubation period of COVID-19: a rapid systematic review and meta-
- analysis of observational research. *BMJ Open* **10**, e039652 (2020).
- 49847. Weiss, A., Jellingsø, M. & Sommer, M. O. A. Spatial and temporal dynamics of SARS-CoV-
- 499 2 in COVID-19 patients: A systematic review and meta-analysis. *EBioMedicine* **58**, 102916
- 500 (2020).
- 50148. Cevik, M. et al. SARS-CoV-2, SARS-CoV, and MERS-CoV viral load dynamics, duration
- of viral shedding, and infectiousness: a systematic review and meta-analysis. *Lancet Microbe*
- 503 **2**, e13–e22 (2021).
- 50449. Benefield, A. E. et al. SARS-CoV-2 viral load peaks prior to symptom onset: a systematic
- review and individual-pooled analysis of coronavirus viral load from 66 studies. *medRxiv*
- 506 2020.09.28.20202028 (2020) doi:10.1101/2020.09.28.20202028.
- 50750. Chandrashekar, A. et al. SARS-CoV-2 infection protects against rechallenge in rhesus
- 508 macaques. *Science* **369**, 812–817 (2020).

- 50951. Mistry, D. et al. Inferring high-resolution human mixing patterns for disease modeling. Nat.
- 510 *Commun.* **12**, 1–12 (2021).
- 51152. Lloyd-Smith, J. O., Schreiber, S. J., Kopp, P. E. & Getz, W. M. Superspreading and the
- effect of individual variation on disease emergence. *Nature* **438**, 355–359 (2005).
- 51353. Taylor, J. Introduction to error analysis, the study of uncertainties in physical measurements.
- 514 (1997).
- 51554. Mood, A. M. On the asymptotic efficiency of certain nonparametric two-sample tests. *Ann.*
- 516 *Math. Stat.* 514–522 (1954).
- 51755. Van Rossum, G. Python Programming Language. in vol. 41 36 (2007).
- 51856. Masad, D. & Kazil, J. MESA: an agent-based modeling framework. in 53–60 (Citeseer,
- 519 2015).

520

521522

523ACKNOWLEDGEMENTS

524The authors are grateful for the computational resources managed and supported by Princeton

525Research Computing, which were used for all simulations in this paper. This work was supported

526by the Foundation for Innovative New Diagnostics.

527AUTHOR CONTRIBUTIONS

528R.L. conceived the study. C.K. and R.B. developed the models and performed the analyses. R.L.,

529S.O., and S.C. provided validation of study findings. C.K. and R.B. prepared the first draft of the

530manuscript; all authors contributed to the revised manuscript.

531**COMPETING INTERESTS**

532The authors declare no potential competing interests.

533**DATA AVAILABILITY**

534All data used in this paper is freely and publicly accessible through the US Center for Disease

26

535Control or peer-reviewed studies. The provided supplement details data sources.

536CODE AVAILABILITY

537The code used in this paper is available upon request and is on GitHub.

FIGURES




Figure 1: Relative infection risk and cost of testing for various RT-PCR scenarios in (A) United States and (B) India. (1) describes the relative infection risk of RT-PCR tests being used at the given frequency and coverage, compared with the scenario with no mitigation. (2) describes the cost of that testing scenario assuming that all susceptible individuals are tested at the appropriate frequency and coverage.




Figure 2: Relative infection risk and cost of testing for various antigen scenarios in (A) United States and (B) India. (1) describes the relative infection risk of antigen tests being used at the given frequency and coverage, compared with the scenario with no mitigation. (2) describes the cost of that testing scenario assuming that all susceptible individuals are tested at the appropriate frequency and coverage.




Figure 3: Disease course in (A) United States and (B) India for antigen testing followed by RT-PCR testing of antigen-negative individuals 100% of the population weekly. Bold lines are the median over 200 independent replicates. Dark-shaded regions are the 25th to 75th percentiles. Light-shaded regions are 2.5th to 97.5th percentiles.




Figure 4: Disease course for (A) United States and (B) India with 20% of the population as initially vaccinated and then 0.25% of the susceptible population being vaccinated each subsequent day; vaccines are coupled with antigen testing (1) 33.3% or (2) 100% of the population weekly. Bold lines are the median over 200 independent replicates. Dark-shaded regions are the 25th to 75th percentiles. Light-shaded regions are 2.5th to 97.5th percentiles.